News for TRACON Pharmaceuticals, Inc. (TCON)

In-vivo CRO industry is projected to witness a CAGR of 7.8% during the period 2024-2032. This growth can be attributed to stringent regulatory landscape...

The metastatic prostate cancer market is driven by advancements in targeted therapies and immunotherapies, catering to a growing aging population. Early...

Tracon Pharmaceuticals ends envafolimab trial after missing endpoint

Loading... Loading... Shares of Broadcom Inc. AVGO rose sharply in today's pre-market trading after the company posted stronger-than-expected results for its s...

Loading... Loading... Shares of Streamline Health Solutions, Inc. STRM fell sharply during Wednesday's session after the company reported worse-than-expected f...

Loading... Loading... U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Wednesday. Following the market opening...

Loading... Loading... Shares of GameStop Corp. GME rose sharply in today's pre-market trading . The rally in the stock came on the back of Keith Gill, also kn...

Research and Development Expenses: $1.9 million for Q1 2024, down from $5 million in Q1 2023.General and Administrative Expenses: $1.4 million for Q1 2024, dec

May 14, 2024 / 08:30PM GMTOperator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals first quarter 2024 earnings conference call. At this ti

TRACON Pharmaceuticals, Inc. (NASDAQ:NASDAQ:TCON) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ETCompany ParticipantsCharles Theuer - President...

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

Shares of Medical Properties Trust, Inc. (NYSE: MPW) rose sharply in today’s pre-market trading after the company announced that it sold its majority interest in Utah Hospitals.

According to DelveInsight’s analysis, the growth of the TROP-2 Inhibitors market is expected to be mainly driven by increasing incidence, a rise in...

Shares of Agenus Inc. (NASDAQ: AGEN) fell sharply during Monday’s session. Agenus disclosed a 1-for-20 reverse stock split of common stock. Agenus Inc. (NASDAQ: AGEN) declined 17% to $0.4181 on Monday.

Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly issued a weak outlook. Ulta Beauty shares dipped 13.7% to $448.08 on Wednesday.

PI3K inhibitors are primarily used in the treatment of various cancers, including breast cancer, lymphoma, and leukemia. With the global burden of cancer...

Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.

The PD-1 and PD-L1 inhibitor market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies and the increase in...